血清 ST8SIA6-AS1 作为肝癌生物标志物的诊断价值。
The Diagnostic Value of Serum ST8SIA6-AS1 as Biomarker in Hepatocellular Carcinoma.
出版信息
Clin Lab. 2020 Dec 1;66(12). doi: 10.7754/Clin.Lab.2020.200231.
BACKGROUND
Long noncoding RNA (lncRNA) is a promising serum biomarker in cancer diagnosis. However, literature on the diagnostic value of the lncRNA for hepatocellular carcinoma (HCC) is scant.
METHODS
The expression of ST8SIA6-AS1 in serum and HCC cell lines was detected by real-time PCR (RT-PCR). We then analyzed the relationship between clinicopathological characteristics and serum ST8SIA6-AS1 expression. In addition, we performed the receiver operating characteristic (ROC) curve and area under curve (AUC) analyses to determine the diagnostic ability of serum ST8SIA6-AS1.
RESULTS
Our data demonstrated an up-regulation of ST8SIA6-AS1 in 77 HCC patients and HCC cell lines. Besides, clinicopathological analysis revealed that ST8SIA6-AS1 corresponds with tumor stages and metastasis, thus might be used for monitoring the HCC progress. Importantly, the ROC analysis demonstrated that ST8SIA6-AS1 yields a superior diagnostic ability. Compared with α-fetoprotein (AFP) alone, a combination of ST8SIA6-AS1 and AFP may achieve more reliable diagnostic results.
CONCLUSIONS
Together, our results demonstrate that serum ST8SIA6-AS1 is a promising serum diagnostic bio-marker for HCC.
背景
长链非编码 RNA（lncRNA）是癌症诊断中有前途的血清生物标志物。然而，关于 lncRNA 对肝细胞癌（HCC）的诊断价值的文献很少。
方法
通过实时 PCR（RT-PCR）检测血清和 HCC 细胞系中 ST8SIA6-AS1 的表达。然后，我们分析了临床病理特征与血清 ST8SIA6-AS1 表达之间的关系。此外，我们进行了接收者操作特征（ROC）曲线和曲线下面积（AUC）分析，以确定血清 ST8SIA6-AS1 的诊断能力。
结果
我们的数据表明，77 例 HCC 患者和 HCC 细胞系中存在 ST8SIA6-AS1 的上调。此外，临床病理分析表明，ST8SIA6-AS1 与肿瘤分期和转移有关，因此可能用于监测 HCC 的进展。重要的是，ROC 分析表明 ST8SIA6-AS1 具有更好的诊断能力。与单独的甲胎蛋白（AFP）相比，ST8SIA6-AS1 和 AFP 的组合可能会获得更可靠的诊断结果。
结论
综上所述，我们的结果表明，血清 ST8SIA6-AS1 是 HCC 有前途的血清诊断生物标志物。
Zotero 插件